🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
02/01/2019 84,10 87,20 82,40 86,60 +1,64% 5,71% 73.365
31/12/2018 84,90 87,30 84,70 85,20 +2,28% 3,06% 20.648
28/12/2018 82,90 84,80 81,90 83,30 +2,71% 3,50% 52.095
27/12/2018 83,20 83,80 80,40 81,10 +0,50% 4,09% 90.100
24/12/2018 81,40 81,40 80,30 80,70 -1,82% 1,35% 16.354
21/12/2018 81,20 83,30 80,70 82,20 +0,00% 3,20% 209.327
20/12/2018 84,50 85,00 81,70 82,20 -6,16% 3,91% 144.565
19/12/2018 87,80 88,90 86,80 87,60 +0,00% 2,39% 61.947
18/12/2018 90,50 90,90 87,60 87,60 -3,84% 3,65% 62.525
17/12/2018 93,10 94,00 88,10 91,10 +1,67% 6,34% 99.195
14/12/2018 90,00 90,70 89,00 89,60 -0,88% 1,89% 56.908
13/12/2018 91,50 92,50 89,90 90,40 -0,44% 2,84% 67.943
12/12/2018 89,00 91,10 88,30 90,80 +2,14% 3,15% 66.306
11/12/2018 88,30 89,80 87,90 88,90 +1,02% 2,15% 102.263
10/12/2018 89,50 90,00 87,40 88,00 -1,79% 2,91% 68.887
07/12/2018 90,60 92,30 89,50 89,60 -0,67% 3,09% 82.369
06/12/2018 90,40 91,00 87,70 90,20 -1,31% 3,65% 106.484
05/12/2018 93,30 94,60 90,90 91,40 -4,19% 3,97% 78.729
04/12/2018 95,00 96,80 93,70 95,40 -1,45% 3,26% 263.371
03/12/2018 97,10 98,60 92,00 96,80 +12,69% 6,80% 451.334
30/11/2018 84,20 86,40 83,60 85,90 +4,76% 3,33% 844.871
29/11/2018 83,40 87,00 81,40 82,00 -2,15% 6,71% 176.090
28/11/2018 83,20 85,00 81,30 83,80 +0,60% 4,45% 105.919
27/11/2018 82,40 85,20 82,00 83,30 +0,60% 3,88% 121.005
26/11/2018 82,00 83,90 81,60 82,80 +2,60% 2,80% 95.442
23/11/2018 78,00 81,10 77,60 80,70 +2,67% 4,49% 56.001
22/11/2018 79,00 80,70 77,30 78,60 +0,51% 4,30% 45.983
21/11/2018 75,60 79,00 75,00 78,20 +4,27% 5,29% 93.285
20/11/2018 77,70 77,70 72,00 75,00 -6,48% 7,34% 245.777
19/11/2018 82,20 83,80 80,10 80,20 -2,55% 4,50% 87.071